Literature DB >> 28738534

High expression of CD47 predicts adverse prognosis in Chinese patients and suppresses immune response in melanoma.

Wenhua Fu1, Jisen Li2, Wei Zhang1, Peng Li1.   

Abstract

BACKGROUND: Cluster of differentiation 47 (CD47) negatively regulates macrophage phagocytosis and is correlated with adverse survival of multiple cancers. In melanoma patients, especially in Chinese melanoma patients, its prognostic value is unclear. In this study, we aim to study the prognostic value of CD47 in a Chinse melanoma patient cohort and its immunomodulation roles in mouse model.
METHOD: 164 melanoma tissue specimens were collected. The expression of CD47 in these clinical samples was examined by immunohistochemistry staining (IHC). The correlation between CD47 expression and clinicopathological parameters was assessed by statistical analysis. Prognostic values CD47 expression were also investigated. In an animal model, effects of CD47 expression on immune infiltration were examined.
RESULTS: CD47 expression was positively correlated with TNM stage, distant metastasis, and death of melanoma patients with the P value of 0.008, 0.018, and 0.032 respectively. High expression of CD47 was an independent prognostic marker of overall survival (HR=1.563, 95% CI: 1.069-2.285) and progression free survival (HR=1.542, 95% CI: 1.053-2.258) of Chinese melanoma patients.
CONCLUSION: In conclusion, high expression of CD47 predicted poor survival in a Chinese melanoma patient cohort and impaired antitumor immune response in the animal model. Targeting CD47 might be a novel option for melanoma patients.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  CD47; Immune response; Melanoma; Prognosis; Survival

Mesh:

Substances:

Year:  2017        PMID: 28738534     DOI: 10.1016/j.biopha.2017.06.030

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.

Authors:  Mingsu Shi; Yun Gu; Kaifeng Jin; Hanji Fang; Yifan Chen; Yifan Cao; Xin Liu; Kunpeng Lv; Xudong He; Chao Lin; Hao Liu; He Li; Hongyong He; Jing Qin; Ruochen Li; Heng Zhang; Weijuan Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

2.  CD47 is a negative regulator of intestinal epithelial cell self-renewal following DSS-induced experimental colitis.

Authors:  Yueqin He; Xinlei Sun; Weiwei Rong; Rong Yang; Hongwei Liang; Ying Qi; Limin Li; Ke Zen
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

Review 3.  Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.

Authors:  Hongcheng Yang; Ruoyang Shao; Hongxin Huang; Xinlong Wang; Zhili Rong; Ying Lin
Journal:  Cancer Med       Date:  2019-06-11       Impact factor: 4.452

Review 4.  WNT Signaling in Tumors: The Way to Evade Drugs and Immunity.

Authors:  Elena Martin-Orozco; Ana Sanchez-Fernandez; Irene Ortiz-Parra; Maria Ayala-San Nicolas
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

5.  Expression of CD47 in Endometrial Cancer and Its Clinicopathological Significance.

Authors:  Mei Yang; Chunfan Jiang; Lin Li; Hui Xing; Li Hong
Journal:  J Oncol       Date:  2022-03-04       Impact factor: 4.375

6.  Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer.

Authors:  Alexandra Giatromanolaki; Achilleas Mitrakas; Ioannis Anestopoulos; Andreas Kontosis; Ioannis M Koukourakis; Aglaia Pappa; Mihalis I Panayiotidis; Michael I Koukourakis
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

7.  MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy.

Authors:  Chen Yang; Tingting Shao; Huihui Zhang; Ninghan Zhang; Xiaoying Shi; Xuejiao Liu; Yao Yao; Linyan Xu; Shengyun Zhu; Jiang Cao; Hai Cheng; Zhiling Yan; Zhenyu Li; Mingshan Niu; Kailin Xu
Journal:  J Transl Med       Date:  2018-10-01       Impact factor: 5.531

Review 8.  Cancer Therapy Targeting CD47/SIRPα.

Authors:  Nazli Dizman; Elizabeth I Buchbinder
Journal:  Cancers (Basel)       Date:  2021-12-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.